Australia already has many of the tools to reverse antimicrobial resistance, but current efforts are not enough. Doing so will require action on everything from antibiotic development to stewardship and prescribing.
Ask Tony Lai whether Australia is winning the fight against antimicrobial resistance (AMR) and his response is measured. ‘I think we’re managing it,’ he says.
As Senior Antimicrobial Stewardship Pharmacist at The Children’s Hospital at Westmead, Mr Lai sees reasons to be positive. Australia has national standards making antimicrobial stewardship (AMS) a requirement for hospital accreditation, there are established controls around how antimicrobials are prescribed, and AMS pharmacists and infectious disease clinicians have the remit to oversee their use.
Compared with many countries, ‘we have it really good’, he says.
But managing resistance isn’t the same as reversing it. The latest surveillance data shows reports of critical antibiotic resistance in Australia rose 25.2% in 2024. That same year, 23.2 million antibiotic prescriptions were supplied through the Pharmaceutical Benefits Scheme (PBS), up 4.8% since 2023. And although 88% of last-line antibiotics in hospitals were prescribed appropriately, only 45% of those used for surgical prophylaxis were.¹
It’s a mixed picture. Overall antibiotic use in Australia is almost 21% lower than it was a decade ago.¹ But the way antibiotics are used, and for how long, continues to drive resistance.
The consequences are already serious, with more than 100 Australian deaths a week estimated to be associated with bacterial AMR.² And as resistance grows, infections will become harder and more expensive to treat.
Resistance is also making some hospital pathogens harder to eliminate. A new Monash University study published in Nature Communications found that when Clostridioides difficile acquires a particular antibiotic resistance gene, it can keep producing spores tough enough to survive hospital-grade disinfectants and high laundry temperatures.³ ‘Antibiotics are helping bacteria evolve in ways we hadn’t anticipated,’ says lead researcher Professor Dena Lyras.
Where are the new antibiotics?
Stewardship can help preserve the antibiotics that are available, but it can’t replace them. There have been no new classes of antibiotics discovered since the 1980s.4 ‘People have been talking about this for years, but the pipeline has really dwindled,’ says Matthew Rawlins, Senior Pharmacist Antimicrobial Stewardship at Perth’s Fiona Stanley Hospital. ‘There are new molecules being created, but they’re really just old ones with something tacked on to protect them a bit better. We see resistance develop almost immediately.’
The traditional pharmaceutical model doesn’t work for antibiotics. Developing and manufacturing a new drug is expensive, yet a successful new antibiotic should be used sparingly to slow the emergence of resistance. High research and development costs combined with deliberately low sales make an unattractive proposition for pharmaceutical companies.
Australia’s funding system creates another barrier. The PBS requires a company to prove its drug is better than alternatives in order to price it higher than existing treatments for the same condition.5
In the United Kingdom, the National Health Service (NHS) has attempted to address what the Organisation for Economic Co-operation and Development describes as a ‘market failure’ through a subscription model.6 Instead of paying companies according to the number of doses sold, it pays a fixed annual fee based on the value an antimicrobial provides to the health system. This ‘break[s] the link between the payments companies receive and the number of their antibiotics prescribed,’ the NHS says.7
Australia is considering a similar approach. The 2024 Health Technology Assessment Review recommended developing and testing flexible reimbursement models for antimicrobials, including a pilot subscription fund.11 Groups including the Australian Antimicrobial Resistance Network have also called on the government to adopt a subscription model.12
The cost of resistance
Resistance increases the cost of care. Multi-drug-resistant infections can mean longer hospital stays, additional infection-control measures, greater need for intensive care and reliance on expensive last-line therapies.13 Australian modelling has estimated that five resistant hospital-associated infections caused almost 46,000 additional hospital bed days and around $72 million in extra hospital costs in 2020.8
Despite the challenges that come with antimicrobials, Mr Rawlins is passionate about the difference pharmacists can make. ‘In practice, we drive it just as much,’ he says of the hospital’s AMS program, which is chaired by an infectious diseases physician. ‘You’ll find pharmacists in AMS advisory roles and committees across the country.’
The work begins with knowing what is being prescribed. Through the National Antimicrobial Utilisation Surveillance Program, hospitals can benchmark their antimicrobial use against their peers.14 If the use of a particular antibiotic begins climbing in one part of the hospital, it gives the AMS team somewhere to look.
‘For example, if we see meropenem use is shooting up in a particular area, we can do targeted audits and education,’ Mr Rawlins says. Pharmacists can then do ward rounds, identify patients receiving the drug and examine whether they should be using the medicine.
‘That’s really my key function on a day-to-day basis,’ he says. ‘Rounding and trying to rationalise therapy.’
Data alone won’t change prescribing
The National Antimicrobial Prescribing Survey (NAPS) adds another layer of information. Rather than only looking at how much is being prescribed, it allows hospitals to assess whether the prescribing is appropriate.15 At Fiona Stanley Hospital, NAPS audit data has helped to change prescribing. ‘At one stage, we could see that urologists were giving antibiotics to everyone who presented with haematuria,’ Mr Rawlins says. ‘It just took us raising it for that to change…It’s pretty rare that we’ll present to a surgical team without changing their practice.’
Mr Lai says data alone isn’t enough to change prescribing – the relationship with prescribers is just as important. ‘There are all these social aspects we have to manage, [including] the soft skills [required to] engage prescribers and change their prescribing behaviour,’ he says.
In paediatrics, where there is often less evidence for antimicrobial use – with many medicines used off label – that relationship can be particularly important. Mr Lai says clinicians often actively seek pharmacists’ advice on dosing, therapeutic drug monitoring and treatment choices.
Mr Rawlins agrees. Although he could conduct AMS rounds without leaving his office, by reviewing electronic records, he deliberately doesn’t. ‘It’s all about visibility and education. We try to get out there and talk to people,’ he says. ‘We get new batches of doctors every 10 to 12 weeks. So you need to keep repeating, repeating, repeating.’
Navigating antimicrobial shortages is another challenge. Mr Lai relies on NSW’s network of AMS pharmacists to share shortage warnings and resources. They also watch overseas supply issues as a ‘canary in the coal mine’.
Mr Rawlins describes the wider Australian response as too reactive. Hospitals stockpile antimicrobials when they can, then source products via the Therapeutic Goods Administration’s Special Access Scheme or Section 19A imports when necessary.
‘We do our best, but the system is not great,’ he says. He wants a more proactive national system capable of identifying impending shortages and securing supply before hospitals are left competing for stock.
On-site stewardship
AMS can be particularly challenging in aged care, where non-specific symptoms, limited on-site diagnostics, workforce turnover and fragmented prescribing arrangements can complicate decision-making.
At Goodwin Aged Care Services, an aged care provider in the ACT and NSW, pharmacist Kirolos Wasef MPS uses Aged Care NAPS data to identify prescribing patterns – including prolonged urinary prophylaxis and treatment of asymptomatic bacteriuria.
‘When I review a resident who is receiving an antimicrobial, I focus on symptoms, diagnostics, guideline alignment and resident‑specific risks. If an antibiotic has been started without clear evidence of infection, I frame the discussion around resident safety and national standards,’ he says.
‘Prescribers are often under time pressure and managing diagnostic uncertainty. My aim is to support them with clear pathways that assist decision-making, rather than simply challenging prescriptions.’
For Mr Wasef, the biggest gains come from embedding stewardship into everyday systems through routine audits and feedback, regular education sessions, clear assessment pathways and consistent governance.
‘When AMS becomes part of everyday workflow, rather than an optional add-on, prescribing improves,’ he says.
The community checkpoint
Community pharmacists are another critical point in the system, with the opportunity to question whether an antimicrobial should be supplied, for how long and in what quantity.
The revision of cautionary advisory label (CAL) D in 2021 is a good starting point. It requires dispensing labels to state, ‘Take [for the number of days] as advised by your prescriber’, replacing decades of advice to take the medicines ‘until all used’ or ‘until all taken’.16 If the duration of therapy is unknown, pharmacists should contact the prescriber for clarification. If the prescriber can’t be reached but it’s important that therapy is commenced, there may be a case for supplying a smaller quantity until it can be confirmed.17
The validity of a prescription should also be considered. Australian data shows antibiotics are sometimes supplied from old prescriptions or repeats.18 Community pharmacists have called for a default 2-week expiry on antibiotic prescriptions, unless manually specified by the prescriber, as well as fewer default repeats and quantities matched to treatment duration rather than pack size.19,20
Mr Rawlins’ advice is to make use of the Therapeutic Guidelines. ‘We’re so lucky to have a resource like that,’ he says. ‘It covers all levels of infection, from life-threatening ICU care to otitis media in a grizzly kid.’
The guidelines themselves show the shifting resistance patterns in Australia. The March 2025 update to the antibiotic guidelines made nitrofurantoin first-line for acute cystitis in adults because of high Escherichia coli resistance to trimethoprim, and added guidance for suspected multidrug-resistant Gram-negative infection.21
There is a new stewardship question as well: with scope of practice expanding, pharmacists are increasingly prescribing antibiotics themselves. This includes for uncomplicated urinary tract infections (UTIs) and, in some jurisdictions, conditions including ear infections and wounds.
Recent evidence on pharmacist-led UTI management is encouraging, with a large-scale NSW and ACT evaluation showing strong protocol adherence and good symptom outcomes.22
At the International Pharmaceutical Federation (FIP) World Congress last year, 82 organisations, including PSA, signed a declaration on AMR, setting out what must happen in order to win the fight.
This included building partnerships, promoting vaccination and disease prevention, promoting the rational use of antibiotics through diagnostic evidence and enhancing public health education, strengthening the global supply chain, and generating evidence on AMR interventions and impact.
‘We will work toward a world where every person has access to essential medicines, safe treatments, and the right care at the right time, leaving no one behind,’ the organisations declared.23
But AMR also reaches well beyond hospitals and pharmacies. Antimicrobials are used in animals and agriculture too, and Australia’s National Antimicrobial Resistance Strategy recognises that resistance ‘affects human and animal health, agriculture, the environment and food sectors’, calling for a coordinated One Health response.24
For now, Mr Lai’s assessment still rings true: Australia is managing AMR. Turning management into reversal will require sustained investment and coordinated action across research, stewardship, prescribing and prevention.
References
- Australian Centre for Disease Control. AURA REPORT: Sixth Australian report on antimicrobial use and resistance in human health. 2026. At: www.amr.gov.au/sites/default/files/2026-02/sixth-australian-report-on-antimicrobial-use-and-resistance-in-human-health-aura-report_0.pdf
- AMR Action + Insights. Overview. At: amr-action.au/overview/
- Srikhanta YN, Bate CE, Ng D, et al. Uncovering an alternate pathway of antibiotic resistance in spore-forming bacteria. Nat Commun. 2026;17:8674. At: doi.org/10.1038/s41467-026-75594-5
- UK Government. Antimicrobial resistance (AMR). 2025. At: www.gov.uk/government/collections/antimicrobial-resistance-amr
- Mintzes B, Hooimeyer A, Chiu K. How drug companies are playing hardball with Australia’s PBS. The Conversation. 2026. At: theconversation.com/how-drug-companies-are-playing-hardball-with-australias-pbs-287161
- UK Parliament Committee of Public Accounts. Antimicrobial resistance: addressing the risks. 2025. At: publications.parliament.uk/pa/cm5901/cmselect/cmpubacc/646/report.html#footnote-112
- NHS England. NHS steps up battle against life-threatening infections following successful world-first pilot. 2023. At: www.england.nhs.uk/2023/07/nhs-steps-up-battle-against-life-threatening-infections-following-successful-world-first-pilot/
- Wozniak TM, Dyda A, Merlo G et al. Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia. Lancet Reg Health West Pac. 2022. At: pmc.ncbi.nlm.nih.gov/articles/PMC9271974/
- CSIRO. Minimising antimicrobial resistance. At: www.csiro.au/en/about/challenges-missions/Antimicrobial-resistance
- Guthrey P. OECD sounds the alarm on antimicrobial resistance. Aus Pharm. 2025. At: www.australianpharmacist.com.au/oecd-sounds-the-alarm-on-antimicrobial-resistance/
- Department of Health. Full recommendations of the Health Technology Assessment Policy and Methods Review. 2024. At: www.health.gov.au/sites/default/files/2024-09/health-technology-assessment-policy-and-methods-review-full-recommendations.pdf
- Australia’s National Roundtable on implementing a pilot subscription model for novel antimicrobials in Australia. Fighting superbugs: the path forward. 2024. At: apo.org.au/sites/default/files/resource-files/2025-07/apo-nid331420.pdf
- World Health Organization. Antimicrobial resistance. 2026. At: www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance
- SA Health. National Antimicrobial Utilisation Surveillance Program. 2026. At: https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/clinical+resources/clinical+programs+and+practice+guidelines/infection+and+injury+management/antimicrobial+stewardship/national+antimicrobial+utilisation+surveillance+program+nausp/national+antimicrobial+utilisation+surveillance+program+nausp
- National Centre for Antimicrobial Stewardship. The National Antimicrobial Prescribing Survey. At: www.ncas-australia.org/National_Antimicrobial_Prescribing_Survey
- Cooke J, Cooper R. New CAL D instruction for antibiotics. Aus Pharm. 2020. At: www.australianpharmacist.com.au/new-cal-d-instruction-antibiotics/
- Wilson HL, Daveson K, Del Mar CB. Optimal antimicrobial duration for common bacterial infections. Aust Prescr. 2019;42(1):5–9. At: australianprescriber.tg.org.au/articles/optimal-antimicrobial-duration-for-common-bacterial-infections.html
- Fredericks I, Hollingworth S, Pudmenzky A, et al. ‘Repeat’ prescriptions and antibiotic resistance: findings from Australian community pharmacy. Int J Pharm Pract. 2017; 25(1):50-58. At: pubmed.ncbi.nlm.nih.gov/27293019/
- Rizvi T, Thompson A, Williams M et al. Perceptions and current practices of community pharmacists regarding antimicrobial stewardship in Tasmania. Int J Clin Pharm. 2018;40(5):1380–1387. At: pmc.ncbi.nlm.nih.gov/articles/PMC6208572/
- Rizvi T, Zaidi STR, Williams M, et al. Factors influencing community pharmacists’ participation in antimicrobial stewardship: a qualitative inquiry. Pharmacy. 2025; 13(2):56. At: www.mdpi.com/2226-4787/13/2/56
- Therapeutic Guidelines. What’s new: antibiotic March 2025. 2025. At: www.tg.org.au/products/therapeutic-guidelines/updates/antibiotic/march-2025/
- Budden M, Martinez-Mardones F, Benrimoj SI, et al. Pathway to Access UTI Management (PATH-UTI): evaluating pharmacist prescribing and management practices for uncomplicated urinary tract infections in community pharmacy in New South Wales and the Australian Capital Territory, Australia. Int J Clin Pharm. 2026. At: link.springer.com/article/10.1007/s11096-026-02226-9
- International Pharmaceutical Federation. The FIP Copenhagen Declaration on Antimicrobial Resistance (AMR). 2025. At: www.fip.org/file/6345
- Department of Health. Australia’s National Antimicrobial Resistance Strategy – 2020 and beyond. 2020. At: www.amr.gov.au/sites/default/files/2022-11/australia-s-national-antimicrobial-resistance-strategy-2020-and-beyond_0.pdf










